Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × contrast agent BR1 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3 Neoplasms, Nerve Tissue 2 Glioma 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Brain Neoplasms 2 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Fibrosis 1 Carcinoma, Pancreatic Ductal 1

Interventions

Docetaxel 244 Prednisone 196 enzalutamide 149 Leuprolide 146 Radiotherapy 139 Abiraterone Acetate 126 Magnetic Resonance Spectroscopy 123 bicalutamide 111 Goserelin 111 Androgen Antagonists 92 Radiosurgery 89 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 88 apalutamide 65 gallium 68 PSMA-11 60 abiraterone 59 Specimen Handling 59 Radiation 50 Gonadotropin-Releasing Hormone 49 darolutamide 47 cabazitaxel 43 Triptorelin Pamoate 43 Brachytherapy 43 pembrolizumab 42 Zoledronic Acid 40 Carboplatin 40 luprolide acetate gel depot 39 Estramustine 39 Biopsy 39 Standard of Care 38 Pluvicto 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01481441 2016-07-06

AMC_2011_190

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase NA Terminated

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡